Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy.
作者： Noah S Scheinfeld , Barry Sloan
DOI:
关键词: Lung cancer 、 Breast cancer 、 Cancer research 、 Combination therapy 、 Medicine 、 Pazopanib 、 Tyrosine-kinase inhibitor 、 Lapatinib 、 Growth factor receptor 、 Tyrosine kinase
摘要: Pazopanib, which is being developed by GlaxoSmithKline plc, is an oral, second-generation multi-targeted tyrosine kinase inhibitor that targets VEGFR, platelet-derived growth factor …
参考文章(0)